Blog
RSS FeedPosted by Michael Wonder on 09 Mar 2020
Regulating medicines in a globalised world with increased recognition and reliance among regulators
5 March 2020 - Research and development of pharmaceuticals are now complex global endeavours, with drug companies operating worldwide using global ...
Posted by Michael Wonder on 05 Aug 2015
Clovis Oncology receives breakthrough therapy designation for CO-1686 for the second-line treatment of EGFR mutant non small-cell lung cancer in patients with the T790M mutation
Clovis Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Company’s investigational agent CO-1686 ...